As previously reported, Wells Fargo analyst Mohit Bansal downgraded Merck to Equal Weight from Overweight with a price target of $115, down from $120. The recent appreciation of the stock brings shares to a level where they seem "fairly valued" and there is a lack of near-term catalysts, the analyst tells investors. Keytruda loss of exclusivity issues persist, which potentially caps the valuation, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRK:
- Merck downgraded to Equal Weight from Overweight at Wells Fargo
- Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint
- Merck price target raised to $130 from $125 at Berenberg
- Merck price target raised to $123 from $116 at Guggenheim
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call